Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

Abstract Background The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. Methods We retrospectively analyzed data from breast cancer patients who bega...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fan Yang, Xiang Huang, Chunxiao Sun, Jianbin Li, Biyun Wang, Min Yan, Feng Jin, Haibo Wang, Jin Zhang, Peifen Fu, Tianyu Zeng, Jian Wang, Wei Li, Yongfei Li, Mengzhu Yang, Jun Li, Hao Wu, Ziyi Fu, Yongmei Yin, Zefei Jiang
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-03-01
Col·lecció:BMC Cancer
Matèries:
Lapatinib
Trastuzumab
Resistance
Breast cancer
Accés en línia:http://link.springer.com/article/10.1186/s12885-020-6639-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars